You are here: Industry Insights > Mylan

News List

Mylan says plant remediation dictated in part by which generics to drop fiercepharma
August 10, 2018
Mylan started a comprehensive remediation of its massive Morgantown, West Virginia, plant in June after the FDA criticized management for weak oversight that led to a myriad of problems at the massive facility.
Mylan Releases Statement on Future of US Business fiercepharma
August 09, 2018
Over the past decade, Mylan's Board of Directors and management team have turned Mylan into a leading global platform with a highly-diversified portfolio of products across broad therapeutic areas and geographies.....
Teva's Copaxone holds its own in wake of Mylan's generic price cut fiercepharma
August 03, 2018
Mylan may have toppled list prices on its generic Copaxone, but Teva isn’t worried. After far surpassing quarterly expectations for the multiple sclerosis blockbuster in the second quarter, the Israeli drugmaker says it’s still on track to rake in signifi
Will Mylan’s big Copaxone price break force Teva’s hand? Clients are pushing already fiercepharma
July 17, 2018
Thanks to Mylan’s gigantic price cut on generic Copaxone from earlier this month, Teva’s going to have to take the price on its branded product down. And it would be wise to start now, one analyst says.
Mylan launches generic version of Novartis’ Exelon Patch pharmaceutical-technology
July 12, 2018
Mylan has launched Rivastigmine Transdermal System, a generic version of Novartis’ Exelon Patch, for the treatment of patients suffering from dementia in the US.
Mylan Launches Generic Exelon Patch americanpharmaceuticalreview
July 11, 2018
Mylan announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch.
Lupin partners with Mylan to commercialise Enbrel Biosimilar financialexpress
June 29, 2018
Through the partnership agreement, Mylan will commercialise Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia
Mylan and Biocon's Fulphila becomes first FDA-approved biosimilar of Amgen's Neulasta pharmafile
June 07, 2018
The FDA has granted approval to Mylan and Biocon’s Fulphila, the first biosimilar version of Amgen’s Neulasta (pegfilgrastim) to be approved in the US.
Mylan lands biosimilar sucker punch to Amgen’s blockbuster pharmafile
June 07, 2018
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to snatch a chunk of the treatment’s $4.2 billion per year in sales, as recorded last year.
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval fiercepharma
June 06, 2018
With an FDA approval for Fulphila, the first U.S. biosimilar to Amgen's Neulasta, Mylan will have its chance to launch a biosim to one of the biggest drug targets in the U.S. market.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page